Germline predisposition in myeloproliferative neoplasms.
One in four people diagnosed with blood cancers may carry inherited genetic risks, suggesting routine genetic testing could reshape treatment planning and family screening.
This review frames hereditary MPNs within the broader hereditary hematopoietic malignancy (HHM) syndrome context, reporting pathogenic germline variant diagnostic yields of 8-27% in apparently sporadic MPN patients depending on testing methodology and population. The authors discuss germline testing criteria, personalized stem cell transplant decision-making, and barriers to developing precision therapies—concluding with a call for broader universal germline testing in MPN patients.
What the study was
- Study design
- narrative_review
- Population
- MPN patients including apparently sporadic cases undergoing germline testing; hereditarily predisposed families
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Semin Hematol
Why it surfaced
Semin Hematol review consolidating emerging evidence that 8-27% of sporadic MPNs harbor germline variants, providing practical guidance on testing strategies and SCT implications—directly relevant for identifying hereditary risk in MPN families and informing transplant decisions in this defined subset.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.